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Liver diseases contribute markedly to the global burden of mor-
tality and disease. This paper provides an overview from a global
perspective of the contribution of alcohol to liver diseases.
The Global Burden of Disease study methodology was used to
estimate the burden of alcohol-attributable liver cirrhosis and
alcohol-attributable liver cancer in 2010 as measured by deaths
and disability adjusted life years (DALYs). This methodology esti-
mates attributable fractions based on alcohol exposure distribu-
tion and relative risks associated with different levels of drinking.
Globally, in 2010, alcohol-attributable liver cirrhosis was
responsible for 493,300 deaths (156,900 female deaths and
336,400 male deaths) and 14,544,000 DALYs (4,112,000 DALYs
for women and 10,432,000 DALYs for men), representing 0.9%
(0.7% for women and 1.2% for men) of all global deaths and
0.6% (0.4% for women and 0.8% for men) of all global DALYs,
and 47.9% of all liver cirrhosis deaths (46.5% for women and
48.5% for men) and 46.9% of all liver cirrhosis DALYs (44.5% for
women and 47.9% for men). Alcohol-attributable liver cancer
was responsible for 80,600 deaths (14,800 female deaths and
65,900 male deaths) and 2,142,000 DALYs (335,000 DALYs for
women and 1,807,000 DALYs for men).
The burden of alcohol-attributable liver cirrhosis and liver can-
cer is high and entirely preventable. Interventions to reduce alco-
hol consumption are recommended as a population health
priority and may range from taxation increases for alcoholic bev-
erages to increases in screening and treatment rates for alcohol
use disorders.
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The global burden of liver diseases
Liver diseases have been found to contribute markedly to the glo-
bal burden of mortality and morbidity [1,2]. In the 2010 Global
Burden of Disease (GDB) study, more than one million deaths
(1,030,800 deaths representing 2.0% of all deaths, 1.4% of all
deaths of women and 2.4% of all deaths of men) and 31,027,000
Disability Adjusted Life Years (DALYs) (1.2% of all DALYs, 0.8%
of all DALYs for women, 1.6% of all DALYs for men) were due to
liver cirrhosis. A DALY here denotes a summary measure for bur-
den of disease, which is composed of the addition of years of life
lost to premature mortality and years of life lost to disability.
Another 752,100 deaths (representing 1.4% of all deaths, 1.0% of
all deaths of women and 1.8% of all deaths of men) and
19,111,000 DALYs (0.8% of all DALYs, 0.5% of all DALYs for women
and 1.0% of all DALYs for men) were due to liver cancer. The
health burden for both diseases is considerably more pronounced
in men with 67% of liver cirrhosis deaths and 69% of liver cancer
deaths involving men, and 70% of DALYs due to liver cirrhosis and
73% of DALYs due to liver cancer in each case for men.
Alcohol and liver disease
Alcohol is consumed widely in most parts of the world and has
long been identiﬁed as a major risk factor for all liver diseases
[3]; for modern overviews see [4–6]. Even though the majority
of adults are still abstainers, almost half of the world’s population
consumed alcohol in the past year [7]. It is the aim of this paper
to provide an overview from a global perspective of the contribu-
tion of alcohol to liver diseases.
Alcoholic liver disease – pathology and biological pathways
The International Classiﬁcation of Diseases (ICD-10) recognizes
several forms of alcoholic liver disease (ALD; see ICD-10, K70),
sometimes considered stages [8], that range from relatively mild
and reversible alcoholic hepatic steatosis (fatty liver) (K70.0) and
alcoholic hepatitis (K70.1), to alcoholic ﬁbrosis and sclerosis of
the liver (K70.2), and further to severe and irreversible stages
of ALD, such as alcoholic liver cirrhosis (K70.3) and alcoholic
hepatic failure (K70.4).13 vol. 59 j 160–168
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Pathogenesis of speciﬁc forms of ALD is covered extensively in
the EASL Clinical Practical Guidelines for the management of ALD
[9]. In short, alcohol consumption, especially heavy consumption,
induces changes in lipid metabolism (increases lipogenesis and
mobilization of lipids and simultaneously decreases hepatic lipid
catabolism), resulting in accumulation of lipids in hepatocytes
called fatty liver. In some cases, alcohol consumption causes an
inﬂammatory response, known as alcoholic hepatitis or steato-
hepatitis if it is accompanied by hepatic lipid deposition. Though
hepatic steatosis and alcoholic hepatitis do not normally cause
irreversible hepatocellular changes, persistence and severity of
these conditions eventually lead to ﬁbrosis and sclerotic changes
in the liver that result in liver cirrhosis due to insidious replace-
ment of hepatocytes with connective tissue, and subsequent liver
failure.
Diagnosis of ALD is based on various clinical and laboratory
ﬁndings and conﬁrmation of alcohol as the etiological factor
[10,11]. Clinical symptoms of ALD vary from asymptomatic hepa-
tic steatosis to malaise, anorexia, weight loss, abdominal discom-
fort, tender hepatomegaly, jaundice, and remote sequelae of liver
dysfunction characteristic of more advanced forms of disease.
Differentiation between ALD and liver disease not due to alcohol
consumption is often made by a history of regular alcohol con-
sumption above the threshold of 20 grams of pure ethanol per
day for women and 30 grams of pure alcohol per day for men
[9,12]; however, the risk curve between the level of alcohol con-
sumption and liver disease is exponential, so ALD is more often
associated with much higher levels of consumption [5,13,14].
Laboratory ﬁndings can be used to describe the severity of ALD
and might be indicative of recent alcohol consumption. Differen-
tiation between the forms of ALD is based on speciﬁc imaging or
histological ﬁndings [15,16]; for a more detailed description see
[9].
In addition, consumption of alcohol can also cause liver cancer
through similar biological pathways [6]. This condition will be
discussed later in our review.Organization of the paper
We start with an overview of available data at the global level,
and with the methodology used to estimate the proportion of
the health burden caused by alcohol-attributable liver cirrhosis
and liver cancer. After presenting the results of our estimations,
we discuss potential interventions to reduce the burden of ALDs,
and the implications of these interventions.Materials and methods
Global data availability
While alcoholic liver cirrhosis and other ALDs constitute a large portion of all liver
disease (e.g., more than 75% of all liver cirrhosis in the European Union in 2004
was estimated to be caused by alcohol [17]; for earlier estimates of global ﬁgures
see [18]), the incidence of ALDs cannot be reliably estimated for all regions of the
world as causes of death are often based on verbal autopsies, which remain the
main method underlying global mortality statistics [19,20]. In fact, ALDs cannot
be reliably estimated in the small number of countries with vital registries, as
the assessment of whether a liver disease is due to alcohol consumption or other-
wise is highly impacted by socio-cultural factors. For instance, in their seminal
study in 12 cities in 10 countries, Puffer and Grifﬁth [21] found that after trian-
gulating data on death certiﬁcates with data from hospital records and interviewsJournal of Hepatology 201(attending physicians, family members), the number of deaths assigned to alco-
holic liver cirrhosis more than doubled, with the majority of new cases being
re-coded from categories of cirrhosis which do not mention alcohol. This
under-reporting has persisted in later studies [22], and seems to be the case for
all alcohol-attributable disease categories [23] which are impacted by stigma,
including, but not limited to, the disclosure of heavy alcohol consumption and
alcohol use disorders [24]. As one consequence, alcohol use disorders are cur-
rently the least treated mental disorder [25,26].
The 2010 GBD study attempted estimates of liver cirrhosis and cancer ‘‘sec-
ondary to alcohol use’’ [1,2,27]. While the methods used to calculate these esti-
mates were not part of the publications, the limitations speciﬁed above apply,
and should be kept in mind when interpreting the data. For the speciﬁc secondary
causes of liver cirrhosis and liver cancer, liver cirrhosis secondary to alcohol use
for 2010 was estimated to be 282,800 deaths and 8,575,000 DALYs (representing
19.8% and 19.8% of all liver cirrhosis deaths and DALYs in 2010, respectively). The
mortality and DALYs from liver cancer secondary to alcohol for 2010 was esti-
mated to be 149,000 deaths and 3,782,000 DALYs (representing 27.4% and
27.6% of all liver cirrhosis deaths and DALYs in 2010, respectively). The full bur-
den of liver cirrhosis and liver cancer attributable to alcohol is not reﬂected in the
deaths or DALYs secondary to alcohol use, as speciﬁed. Not only is there a stigma
attached to the labelling of heavy alcohol use or abuse as a cause of disease or
mortality, but such alcohol consumption often interacts with other secondary
causes of death, such as hepatitis B. Thus, a person, who develops liver disease
secondary to hepatitis B and who consumes alcohol while living with the disease,
has a markedly increased risk of mortality compared to a person who develops
liver disease secondary to hepatitis B but abstains from alcohol consumption.
As a result, some of the burden of liver disease secondary to hepatitis B, hepatitis
C, or other causes is attributable to alcohol (i.e., outcomes, that would not have
occurred if alcohol had not been consumed [28,29]).
Given the lack of reliable direct estimates of mortality and the burden of dis-
ease due to ALD, we estimated the burden of alcohol-attributable liver cirrhosis
indirectly using standard epidemiological methodology. We used the respective
GBD study category for liver cirrhosis, which comprises all of the K70 codes,
and estimated the proportion of alcohol-attributable liver cirrhosis based on
the prevalence of alcohol consumption and the risk relations between levels of
consumption and the disease outcomes (for details see the next section).
Data sources and statistical model
To estimate the number of deaths, potential years of life lost (PYLL), years lived
with disability (YLD), and DALYs from liver cirrhosis and liver cancer that are
attributable to alcohol consumption, we combined the risks of each of liver cir-
rhosis and liver cancer with the prevalence of alcohol exposure using alcohol-
attributable fractions (AAF) calculated using the 2010 GBD study methodology
[30,31]. AAFs represent the proportion of each outcome that would not have
occurred in a counterfactual scenario where no one consumes alcohol (see
[29,32] for more information on attributable fractions). The method to calculate
the number of deaths, PYLL, YLD, and DALYs attributable to alcohol consumption
has two main steps: (1) calculation of the race-, age-, sex-, and consumption-spe-
ciﬁc AAFs, and then (2) application of these AAFs to the corresponding mortality,
PYLL, YLD, and DALYs data (see [1,2,27] for an overview of GBD study procedures
to calculate these outcome indicators). For details on the model please see the
section on statistical models below.
All data were available by age and sex at the regional level. Regions were
deﬁned in accordance with the 2010 GBD study [30]. Grouping of countries into
regions was determined by geographical location and epidemiological proﬁle
(child and adult mortality levels and major causes of death). Neither income
nor population of the countries in a region had an impact on the grouping struc-
ture. The countries included within each GBD region are described in Supplemen-
tary data 1.Alcohol consumption data
Data on alcohol consumption and drinking patterns were obtained for 2005 and
estimated for 2010 (see [33] for country- and region-speciﬁc data on alcohol con-
sumption and patterns). Data for recorded, unrecorded and tourist per capita con-
sumption of pure alcohol (ethanol) were obtained from the Global Information
System on Alcohol and Health [34] based on surveys conducted by the WHO
and regularly published in the Global Status Reports on Alcohol and Health (for
the most recent report see: [7]). The prevalence of lifetime abstainers (people
who have never consumed one standard drink of alcohol), former drinkers (peo-
ple who have consumed alcohol but have not done so within the past year), and
current drinkers were obtained from large, nationally representative surveys in
the respective countries [33].3 vol. 59 j 160–168 161
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Alcohol consumption was modeled using data on per capita consumption tri-
angulated with data on the prevalence of current drinkers and using methods
described elsewhere [35,36].
Mortality data
Data on the number of deaths, PYLL, YLD, and DALYs for all causes, malignant
neoplasms (ICD-10 codes: C00–C97), liver cirrhosis (K70 and K74), and liver can-
cer (C22) were obtained from the 2010 GBD study [1,2,27].
Risks of liver cancer and liver cirrhosis
Relative risk (RR) estimates for liver cirrhosis were obtained from a meta-analysis
performed by Rehm and colleagues [5] and the RR estimates for liver cancer were
obtained from a meta-analysis performed by Corrao and colleagues [37] (see Sup-
plementary data 2 for graphs of the RR functions differentiated by sex for liver cir-
rhosis and liver cancer).
Statistical modeling
The following formula was used to derive the AAF:
AAF ¼ Pabstainers þ PFormer drinkersRRFormer drinkers þ
R 150
>0 PCurrent drinkersðxÞRRCurrent drinkersðxÞ  1
Pabstainers þ PFormer drinkersRRFormer drinkers þ
R 150
>0 PCurrent drinkersðxÞRRCurrent drinkersðxÞ
where Pabstainers, PFormer_drinkers and PCurrent_drinkers (x) represent the prevalence of
abstainers, former drinkers and current drinkers (given an average daily alcohol
consumption of x), respectively. RRFormer_drinkers and RRCurrent_drinkers (x) represent
the risk of liver cirrhosis or liver cancer for former drinkers and current drinkers
(given an average daily alcohol consumption of x) relative to the risk of liver cir-
rhosis or liver cancer for lifetime abstainers. For more information on how AAFs
are calculated see [38].
Age- and sex-speciﬁc population data for 2010 were obtained from the 2010
GBD study based on UN Population Division estimates. Standardized mortality
rates were calculated based on the global population structure.
Association between alcohol-attributable harms and gross domestic product
A linear regression was employed (weighted for population size) to investigate
the association between the number of alcohol-attributable liver cirrhosis and
liver cancer deaths and DALYs per 100,000 people per litre of alcohol consumed
per capita, and gross domestic product adjusted for purchase power parity (GDP
(PPP)). Data on GDP (PPP) for 2010 (measured in current US dollars) was obtained
from The World Bank [39].Results
Global alcohol consumption
Fig. 1 outlines the adult per capita consumption of alcohol by
country for 2010. Eastern Europe had the highest per capita con-
sumption, with 15.7 L per person (8.1 L per woman and 24.9 L per
man), while the GBD region of North Africa/Middle East had the
lowest adult per capita consumption of alcohol, with 1.0 L per
person (0.2 L per woman and 1.7 L per man). Southern Sub-Sah-
aran Africa had the highest per drinker consumption of alcohol,
with 30.3 L of alcohol consumed per drinker in 2010 (37.8 L per
man and 23.0 L per woman). Eastern Europe had the highest pat-
tern of drinking score at 4.9, indicating that people in that region
consumed large quantities of alcohol frequently, often drank to
intoxication, engaged in prolonged binges, and consumed alcohol
mainly outside of meals [40,41]; for a deﬁnition of patterns of
drinking score, see Rehm et al. [42].
Global burden of liver cirrhosis
As indicated above, in 2010 liver cirrhosis was responsible for
1,030,800 deaths and for 31,027,000 DALYs lost. Of all deaths
caused by liver cirrhosis, 493,300 deaths were alcohol-attribut-
able (47.9% of all liver cirrhosis deaths), representing 0.9% of all162 Journal of Hepatology 201deaths due to any cause (0.7% of all deaths of women and 1.2%
of all deaths of men). Of the net burden of disease of mortality
attributable to alcohol consumption in 2010, alcohol-attributable
liver cirrhosis was responsible for 10.4% of this burden (9.3% for
women and 11.0% for men). Table 1 outlines the number of
deaths from liver cirrhosis that are attributable to alcohol con-
sumption, the percentage of all deaths that were due to alco-
hol-attributable liver cirrhosis, and the percentage of all
alcohol-attributable deaths that were due to liver cirrhosis.
Globally, in 2010 7.2 deaths per 100,000 people (4.6 deaths
per 100,000 females and 9.7 deaths per 100,000 males) were
caused by liver cirrhosis attributable to alcohol consumption.
Fig. 2 displays the number of liver cirrhosis deaths per 100,000
people, attributable to alcohol consumption differentiated by
sex and region. Central Asia experienced the greatest number of
alcohol-attributable liver cirrhosis deaths per 100,000 people,
with 17.5 deaths per 100,000 people (14.6 deaths per 100,000
women, and 20.4 deaths per 100,000 men). Central Latin America
had the second highest rate of alcohol-attributable deaths due to
liver cirrhosis, with 15.8 deaths per 100,000 people (7.8 deaths
per 100,000 women, and 23.6 deaths per 100,000 men).
The number of deaths from liver cirrhosis (corrected for pop-
ulation size) attributable to alcohol consumption was much
greater among people 65 years of age and older (31.1 deaths
per 100,000 people) when compared to people 15–34 years of
age (1.0 deaths per 100,000 people) and people 35–64 years of
age (13.1 deaths per 100,000 people). This relationship between
alcohol-attributable deaths from liver cirrhosis and age was
observed for both men and women. In terms of relative contribu-
tions, the impact of alcoholic liver cirrhosis is the greatest in the
middle age group: 4.9%, 62.1%, and 33.0% of all deaths from alco-
hol-attributable liver cirrhosis occurred in people aged 15–34,
35–64, and 65 years and older, respectively.
Of all DALYs due to liver cirrhosis 14,544,000 DALYs were
attributable to alcohol consumption. This represents 0.6% of all
DALYs (0.4% of all DALYs for women and 0.8% of all DALYs for
men) and 10.9% (12.3% for women and 10.5% for men) of all
DALYs attributable to alcohol consumption. See Table 2 for the
number of DALYs from liver cirrhosis that are attributable to alco-
hol consumption, the percentage of all DALYs that were due to
alcohol-attributable liver cirrhosis, and the percentage of all alco-
hol-attributable DALYs due to liver cirrhosis.
Globally, in 2010 there were 211.1 DALYs per 100,000 people
(120.4 DALYs per 100,000 women and 300.3 DALYs per 100,000
men) caused by liver cirrhosis attributable to alcohol consump-
tion. Fig. 3 shows the number of liver cirrhosis DALYs per
100,000 people attributable to alcohol consumption by sex and
region. Central Asia experienced the greatest number of alcohol-
attributable liver cirrhosis DALYs per 100,000 people for both
men and women, with 546.0 DALYs per 100,000 people (435.1
DALYs per 100,000 women, and 655.0 DALYs per 100,000 men).
Eastern Europe had the second highest rate of liver cirrhosis DALYs
due to alcohol consumption,with 456.1DALYs per 100,000 people.
Unlike deaths, the number of DALYs from liver cirrhosis (cor-
rected for population size) attributable to alcohol consumption
was greater among people 35–64 years of age (459.4 DALYs per
100,000 people) when compared to people 15–34 years of age
(59.7 DALYs per 100,000 people) and people 65 years of age
and older (448.5 DALYs per 100,000 people). The relationship
between alcohol-attributable DALYs from liver cirrhosis and age
was observed for both men and women. Of all DALYs from liver3 vol. 59 j 160–168
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Fig. 1. Total adult per capita consumption, in litres of pure alcohol, 2010.
Table 1. Alcohol-attributable deaths caused by liver cirrhosis in 2010.
Global burden of disease 
region
Women  Men  Total
Deaths % of all 
deaths
% of 
alcohol-
attributable 
deaths
 Deaths % of all 
deaths
% of 
alcohol-
attributable 
deaths
 Deaths % of all 
deaths
% of 
alcohol-
attributable 
deaths
7300 1.0 15.3 13,900 1.7 14.3 21,200 1.3 14.6
Asia, Central 5400 2.1 11.7 6800 2.0 9.8 12,200 2.0 10.5
Asia, East 17,100 0.5 8.1 53,300 1.0 9.0 70,500 0.8 8.8
Asia, South 22,700 0.4 16.7 64,900 0.9 14.6 87,500 0.7 15.0
Asia, Southeast 6500 0.4 12.6 27,900 1.3 16.2 34,500 0.9 15.4
Australasia 400 0.5 4.5 800 0.8 5.8 1200 0.7 5.2
Caribbean 900 0.4 8.7 1600 0.6 8.3 2500 0.5 8.4
Europe, Central 6600 1.1 6.9 16,600 2.5 10.3 23,200 1.8 9.0
Europe, Eastern 17,000 1.1 3.7 16,100 1.1 4.1 33,100 1.1 3.9
Europe, Western 19,900 1.0 9.0 32,100 1.6 10.5 52,000 1.3 9.9
Latin America, Andean 1700 1.5 21.1 2200 1.7 15.4 3900 1.6 17.5
Latin America, Central 7600 1.5 20.9 23,900 3.6 20.0 31,500 2.7 20.2
Latin America, Southern 2300 1.1 12.7 4800 2.1 14.8 7100 1.6 14.0
Latin America, Tropical 4500 0.8 11.1 13,600 1.9 12.2 18,100 1.5 11.9
North Africa/Middle East 4500 0.5 18.3 3800 0.3 5.8 8300 0.4 9.2
North America [high income] 13,400 0.9 8.2 19,700 1.4 9.3 33,100 1.1 8.8
Oceania 400 1.0 23.7 500 1.0 18.3 900 1.0 20.4
Sub-Saharan Africa, Central 1700 0.4 16.8 3200 0.5 14.3 5000 0.5 15.0
Sub-Saharan Africa, East 8500 0.6 21.8 12,300 0.8 14.4 20,800 0.7 16.7
Sub-Saharan Africa, Southern 1000 0.3 10.9 2400 0.6 6.1 3400 0.5 7.0
Sub-Saharan Africa, Western 7400 0.5 15.2 15,900 0.9 17.0 23,200 0.7 16.4
World 156,900 0.7 9.3  336,400 1.2 11.0  493,300 0.9 10.4
Asia, Pacific [high income]
JOURNAL OF HEPATOLOGYcirrhosis, 9.7%, 74.1%, and 16.2% occurred in people aged 15–34,
35–64, and 65 years and older, respectively.
TheDALYs due to liver cirrhosisweremainly caused fromyears
of life due to premature mortality rather than due to YLD. Of the
burden of DALYs due to alcohol-attributable mortality, 98.5% ofJournal of Hepatology 201the burden was from PYLL and 1.5% of the burden was from YLD.
The proportion of PYLL to all DALYs ranged from 97.1% (2.9% from
YLD) for theGBD region of East Asia to 99.1% (0.9% fromYLD) in the
Southeast Asia region. Women had a greater proportion of the
alcohol-attributable burden of liver cirrhosis due to YLD (2.4% of3 vol. 59 j 160–168 163
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Fig. 2. Alcohol-attributable liver cirrhosis deaths per 100,000 people in 2010 by sex and region.
Table 2. Alcohol-attributable disability adjusted life years (DALYs) caused by liver cirrhosis in 2010.
Global burden of 
disease region
Women  Men  Total
DALYs % of all 
DALYs
% of all 
alcohol-
attributable 
DALYs
 DALYs % of all 
DALYs
% of all 
alcohol-
attributable 
DALYs
 DALYs % of all 
DALYs
% of all 
alcohol-
attributable 
DALYs
[high income]
106,000 0.5 16.6 359,000 1.5 14.4 465,000 1.1 14.8
Asia, Central 167,000 1.3 17.9 231,000 1.4 10.3 398,000 1.4 12.6
Asia, East 424,000 0.3 9.4 1,625,000 0.8 9.1 2,049,000 0.6 9.2
Asia, South 657,000 0.2 15.2 2,142,000 0.6 13.3 2,799,000 0.4 13.7
Asia, Southeast 174,000 0.2 13.5 923,000 0.9 14.9 1,097,000 0.6 14.6
Australasia 8000 0.3 6.8 19,000 0.6 6.5 28,000 0.5 6.6
Caribbean 21,000 0.2 11.0 46,000 0.3 8.1 68,000 0.3 8.9
Europe, Central 173,000 1.0 11.9 473,000 2.2 11.6 646,000 1.7 11.7
Europe, Eastern 531,000 1.3 7.0 554,000 1.1 4.0 1,085,000 1.2 5.0
Europe, Western 383,000 0.7 13.3 793,000 1.3 11.5 1,176,000 1.0 12.0
Latin America, Andean 42,000 0.6 20.3 70,000 0.9 11.5 113,000 0.8 13.7
Latin America, Central 185,000 0.7 21.3 734,000 2.2 16.8 918,000 1.6 17.6
Latin America, Southern 48,000 0.7 15.1 126,000 1.5 13.5 174,000 1.1 13.9
Latin America, Tropical 120,000 0.5 11.6 462,000 1.4 10.0 582,000 1.0 10.3
North Africa/Middle East 137,000 0.2 20.5 126,000 0.2 5.6 263,000 0.2 9.0
North America 
[high income]
314,000 0.7 13.3 551,000 1.2 10.1 865,000 1.0 11.0
Oceania 13,000 0.6 23.4 17,000 0.7 14.5 30,000 0.6 17.3
Sub-Saharan Africa, 
Central
61,000 0.2 16.6 119,000 0.3 12.1 179,000 0.2 13.3
Sub-Saharan Africa, East 254,000 0.3 18.8 407,000 0.4 11.6 661,000 0.3 13.6
Sub-Saharan Africa,  
Southern
35,000 0.2 9.1 84,000 0.4 4.2 120,000 0.3 5.0
Sub-Saharan Africa, 
Western
258,000 0.2 14.2 570,000 0.4 14.0 827,000 0.3 14.1
World 4,112,000 0.4 12.3  10,432,000 0.8 10.5  14,544,000 0.6 10.9
Asia, Pacific
Review
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DALYs lost) when compared to men (1.1% of DALYs lost). This dif-
ference by sex was observed for all regions (see Supplementary
data 3 for the percentage of DALYs that were attributable to PYLL
and to YLD differentiated by sex and region).
Of the total burden of liver cirrhosis, 47.9% of liver cirrhosis
deaths (46.5% for women and 48.5% for men) and 46.9% of DALYs
(44.5% for women and 47.9% for men) were attributable to alco-
hol consumption. Central Europe had the highest proportion of
liver cirrhosis deaths and DALYs attributable to alcohol consump-
tion, with 72.3% of all liver cirrhosis deaths (62.6% for women and
77.1% for men) being attributable to alcohol consumption and
74.6% of all liver cirrhosis DALYs (67.8% for women and 77.4%
for men) being attributable to alcohol consumption. North
Africa/Middle East had the lowest proportion of liver cirrhosis
deaths and DALYs attributable to alcohol consumption, with
14.0% of all liver cirrhosis deaths and 15.9% of all liver cirrhosis
DALYs attributable to alcohol consumption.
The alcohol-attributable liver cirrhosis deaths and DALYs per
100,000 people per litre of alcohol consumed per capita were sig-
niﬁcantly associated with GDP (PPP). As GDP (PPP) increased by
1,000 USD, the number of alcohol-attributable liver cirrhosis
deaths per 100,000 people per litre of alcohol consumed per capita
decreased by 0.05 (95% conﬁdence interval (CI): 0.01–0.08) and
the number of alcohol-attributable liver cirrhosis DALYs per
100,000 people per litre of alcohol consumed per capita decreased
by 1.44 (95% CI: 0.39–2.49). For comparison, in 2010 the world
average alcohol-attributable liver cirrhosis deaths per 100,000
people per litre of alcohol consumed per capita was 1.31 and the
number of alcohol-attributable liver cirrhosis DALYs per 100,000
people per litre of alcohol consumed per capita was 38.48.
Global burden of liver cancer
In 2010, 337,400 deaths (91,500 female deaths and 245,900 male
deaths) and 8,670,000 DALYs (2,252,000 DALYs for women and
6,418,000 DALYs for men) from malignant neoplasms were
attributable to alcohol consumption. Of these alcohol-attribut-
able malignant neoplasm deaths, 80,600 deaths (14,800 deaths
of women and 65,900 deaths of men) were caused by liver cancer
and were attributable to alcohol consumption. Liver cancer
deaths attributable to alcohol consumption were responsible
for 0.2% of all deaths (0.1% of all deaths of women and 0.2% of
all deaths of men), 10.7% (6.4% for women and 12.7% for men)
of the deaths from liver cancer, 1.7% (0.9% for women and 2.1%
for men) of the net number of alcohol-attributable deaths and
23.9% (16.2% for women and 26.8% for men) of all alcohol-attrib-
utable cancer deaths. Of the DALYs due to malignant neoplasms
attributable to alcohol consumption, 2,142,000 (335,000 DALYs
for women and 1,807,000 DALYs for men) were caused by liver
cancers attributable to alcohol consumption. This represents
0.1% of all DALYs (0.03% of all DALYs for women and 0.1% of all
DALYs for men), 11.2% (6.4% for women and 13.0% for men) of
the DALYs from liver cancer, 1.6% (1.0% for women and 1.8% for
men) of the net number of alcohol-attributable DALYs lost, and
24.7% (14.9% for women and 28.2% for men) of the DALYs from
alcohol-attributable cancers; (see Supplementary data 4 for infor-
mation on the burden of alcohol-attributable liver cancer).
The alcohol-attributable liver cancer deaths and DALYs per
100,000 people per litre of alcohol consumed per capita were
not signiﬁcantly associated with GDP (PPP).Journal of Hepatology 201Key Points
• The burden of alcoholic liver diseases is large and
resulted in 493,300 deaths and 14,544,000 disability
adjusted life years (DALYs) in 2010. This burden
represents 0.9% of all deaths and 0.6% of all DALYs
in 2010
• Alcohol is strongly associated with overall liver cirrhosis
rates, with 47.9% of liver cirrhosis deaths (46.5% of
women and 48.5% of men) and 46.9% of DALYs lost
from liver cirrhosis (44.5% for women and 47.9% for
men) attributable to alcohol consumption
• Alcohol-attributable liver cancer was responsible
for 80,600 deaths and 2,142,000 DALYs in 2010,
representing 0.15% of all deaths and 0.09% of all
DALYs lost globally
• To reduce the burden of alcoholic liver diseases and
alcoholic liver cancer, interventions are required
to reduce alcohol consumption, including taxation
increases and increases in treatment rates for alcohol
use disorders
• In addition, clinical interventions for alcoholic liver
disease should focus on timely treatment of its initial,
reversible, stages, via screening and early detection of
alcohol use disordersDiscussion
Before discussing the implications of our results, the potential
limitations of our research should be addressed. When reading
our numbers it should be kept in mind that for both diseases
the estimation of alcohol-attributable fractions was made indi-
rectly, by combining distribution of exposure and risk relations.
Thus, we avoid the subjectivity of a direct diagnosis for alcoholic
liver cirrhosis, but we introduce potential other biases. Each
review or summary analysis is only as reliable as the underlying
data and since our analyses are dependent on three main sources
of data, namely, exposure to alcohol, estimates of the mortality
and disease burden, and the risk relations between exposure
and outcome, the validity and reliability of these components
must be considered. Alcohol consumption consists of recorded
and unrecorded consumption data [42,43], which, in comparison
to other risk exposures, is fairly reliable at the country level
[7,31,44], even though the unrecorded consumption data contain
more measurement error.
With respect to risk relations, the analyses contained in this
paper are often limited by the use of one-time measurements
of exposure when calculating the alcohol-attributable burden of
liver cirrhosis and liver cancer. The exclusion of past patterns of
drinking is problematic when studying the role of alcohol in
the development of long-developing diseases, such as malignant
neoplasms, where the time between exposure(s) to a carcinogen
and exhibiting symptoms of cancer can range from between 15
and 30 years [45]. Liver cirrhosis at the individual level is also3 vol. 59 j 160–168 165
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Fig. 3. Alcohol-attributable liver cirrhosis disability adjusted life years (DALYs) per 100,000 people in 2010 by sex and region.
Reviewaffected mainly by long-term heavy drinking; however, an imme-
diate decrease in the incidence of liver cirrhosis is seen at the
country level, a short time after decreases in alcohol consumption
[46,47]. For example, the Gorbachev reforms involving a substan-
tial decrease of alcohol resulted in a marked immediate decrease
of liver cirrhosis mortality [48]. Similar observations were made
in France during the World War II occupation, when alcohol
was conﬁscated [46]. Thus, estimates presented in this paper
for 2010 should be accurate as most cases of mortality are trig-
gered by the recent heavy use of alcohol [47].
Another potential limitation of the methodology used to cal-
culate the alcohol-attributable burden of liver cancer and of liver
cirrhosis is the use of adjusted RR functions. The AAF formulas
used in our analysis rely on the assumption that the RR functions
are unadjusted, and therefore the use of RR functions from meta-
analyses (where adjusted RR estimates were used) in our analysis
may have introduced an error into our results [49]. However, this
error should have no noticeable effect on the results, since most
analyses show no marked differences after adjustment for the
usual risk factors tested (see [4] for an overview of relevant
meta-analyses). In addition, if unadjusted RR functions had been
used in our analysis, our results would have been more limited.
This is because only a small proportion of older studies could
have been included if we had used unadjusted RR functions,
which would have led to inaccurate estimates of the number of
alcohol-attributable deaths. It should be noted that in risk analy-
ses, such as the Comparative Risk Assessment for the GBD studies
[44], almost all of the underlying studies for the different risk fac-
tors only report adjusted RR estimates. The need for adjustment
to the RR functions may change when other dimensions of alco-
hol consumption, such as frequency of heavy drinking occasions,
are considered.
The burden of ALDs is huge on a global level. The most direct
clinical approach to minimizing the burden of ALD would be
timely treatment of its initial, reversible, stages of disease. Given
that in early stages ALD is often asymptomatic and can only be
identiﬁed by laboratory ﬁndings [9], a focus on screening for alco-
hol use disorders and their treatment [50,51] seems to be the
most feasible approach for prevention of ALD. At the same time,166 Journal of Hepatology 201given that alcohol use disorders are very likely to be accompanied
by at least a mild form of ALD, clinicians should approach treat-
ment of alcohol use disorders with the prevention and potential
treatment of ALD in mind. Thus, treatment should include psy-
chosocial and pharmacotherapies – treatment of alcohol use dis-
orders, treatment of alcohol liver disease, correction of
nutritional status, etc. Prescription of the most widely used phar-
macotherapies for alcohol use disorders, i.e., disulﬁram, naltrex-
one and acamprosate, should be considered after assessment of
ALD, and in cases of advanced ALD preference should be given
to medications that are not hepatotoxic [9].
In principle, all burden associated with ALD is avoidable [28],
but prevention is difﬁcult as it attempts to change culturally
engrained habits such as heavy alcohol consumption. To combat
this burden, the World Health Organization has recently
launched a global strategy to reduce the harmful use of alcohol
[52], building on earlier recommendations [53,54]. This global
strategy focuses on ten key areas of policy options and interven-
tions at the national level and four priority areas for global action.
The ten areas for national action include health services’ response
and community action, but focus on preventive public health
actions such as drink-driving policies and countermeasures;
reductions of availability of alcohol; ban of marketing of alcoholic
beverages; and increase of prices (i.e., via taxation). It also
includes harm reduction measures to reduce the negative conse-
quences of drinking and alcohol intoxication of those who drink.
Other foci refer to a reduction of unrecorded illicit and informally
produced alcohol, and the establishment of a monitoring and sur-
veillance system [52].
Most of these measures are not only effective but also cost-
effective, with taxation increases to increase the price of alcoholic
beverages, reductions of availability of alcohol, and bans of its
marketing being identiﬁed as ‘‘best buys’’ for the reduction of
alcohol-attributable harm [54–56].
The global burden of ALDs strongly reinforces the necessity of
implementing such public health strategies to prevent alcohol-
attributable harm, even though to do so may not always be the
most popular with politicians who tend to focus on education
or individual-based responses [50,57].3 vol. 59 j 160–168
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